Login to Your Account

Biogen Idec's MS Therapy Yields Positive Results in Phase III

By Catherine Shaffer
Staff Writer

Friday, January 25, 2013
Biogen Idec Inc.'s peginterferon beta-1a produced a significant reduction in annualized relapse rate in patients with multiple sclerosis according to primary efficacy analysis from a Phase III study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription